MODIFIEO PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

P E Substitute for form 1449B/PTO		Complete If Known		
THEORMATION DISCLOSURE	Application Number	10/522,130		
D WFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	01/19/2005		
101000 8	First Named Inventor	Murray Goodman		
FED &	Group Art Unit			
(use as many sheets as necessary)	Examiner Name			
Sheeta 95 1 of 2	Attomey Docket Number	SDUC1100J-1 (041673-3109)		

				U.S. PATENT DOCUMENTS		
Examiner Initials*		U.S. Patent I	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No.1	Number	Kind Code ² (if known)			

Examiner Initials*	Cite	Fo	oreign Patent D		Name of Patentee or	Date of Publication of Cited Occument	Pages, Columns, Lines, Where Relevant	1
	No.1	Office ³ Number ⁴ Kind Code ⁵ (if known)			Applicant of Cited Documents	MM-00-YYYY	Passages or Relevant Figures Appear	1e
	A1	wo	91/09958		Whitehead Institute for Biomedical Research	07-11-1991		
	A2	wo	94/04686		Biogen, Inc.	03-03-1994		
	A3	wo	98/52614		The Board of Trustees of the Leland Stanford Junior University	11-26-1998		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T€
	A4	BUSCHLE, M. et el., Transloading of tumor entigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA., 94, p. 3256-3261 (1997).	
	A5	EMI, N. et al., Gene Transfer Mediated by Polyarginine Requires a Formation of Big Carrier-Complex of DNA Aggregate, Biophys. Res. Commun., 231, p. 421-424 (1997).	
	A6	FEICHTINGER, L. et al., Triurethane-Protected Guanidines and Triffydiurethane-Protected Guanidines: New Reagents for Guanidinylation Reactions, J. Org. Chem., 63, p. 8432 (1998).	
	A7	LEONETTI, JP. et al., Biological Activity of Oligonucleotide-Poly(L-lysine) Conjugates: Mechanism of Cell Uptake, Bioconjugate Chem., 1, p. 149-153 (1990).	
	A8	MITCHELL, D.J. et al., Polyargine enters cells more efficiently than other polycationic homopolymers, J. Peptide Res., 55 p. 318-325 (2000).	
	A 9	MURPHY, J.E. et al., A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery, Proc. Natl. Acad. Sci. USA., 95, p. 1517-1522 (1998).	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Unique citation designation number: *See attached Kinds of U.S. Patent Documents, *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English tanguage Translation is attached.

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450. Alexandria, VA 22313-1450. OO NOT SENO FEES OR COMPLETEO FORMS TO THIS ADDRESS. SENO TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DLMR_280342.1

MODIFIED PTO/SB/08 (08-0C
Approved for use through 10/31/2002. OMB 0651-003
U.S. Patent and Trademark Office: U.S. OEPARTMENT OF COMMERCI
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form	n 1449B/	PTO	Complete If Known		
	INFORMATION D	DISCLO	SURE	Application Number	10/522,130	
	STATEMENT BY	APPLI	CANT	Filing Date	01/19/2005	
				First Named Inventor	Murray Goodman	
				Group Art Unit		
	(use as many sheet	ts as ne	cessary)	Examiner Name		
Sheet	2	of	2	Attomey Docket Number	SDUC1100J-1 (041673-3109)	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
	A10	PEPINSKY, R.B. et al., Specific Inhibition of a Human Papillomavirus E2 <i>Trans</i> -Activator by Intracellular Delivery of Its Repressor, DNA Cell Biol., 13, p. 1011-1019 (1994).
	A11	RYSER, H.JP., A Membrane Effect of Basic Polymers dependent on Molecular Size, Nature (London), 215, p. 934-936 (1967).
	A12	overcomes drug resistance in cultured cells, Proc. Nat. Acad. Sci. USA., 75, p. 3867-3870 (1978).
	A13	SCHWARZE, S.R. et al., In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Science, 285, p. 1569-1572 (1999).
	A14	SHEN, W., et al., Conjugation of poly-L-lysine to albumin and horseradish peroxides: A novel method of enhancing the cellular uptake of proteins, Proc. Nat. Acad. Sci. USA., 75, p. 1872-1876 (1978).
	A15	VOCERO-AKBANI, A.M. et al., Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein, Nat. Med., 5, p. 29-33 (1999).
	A16	WENDER, P.A. et al., The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. Natl. Acad. Sci. USA., 97, p. 13003-13008 (2000).

Examiner Signature	Date Considered
1	the state of the s

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. **Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **For Japanese patent documents, the indication of the year of the reign of the Emiperor must precede the serial number of the patent document. **Wind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. **Applicant is to place a check mark here if English language Translation is attached. Enginsh language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETEO FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OLMR_280342.1